The idea of the alfapump® dates back to 2000 with a physician looking for a better way to manage his ascites patients.
The first prototypes were built in 2005 and the founders demonstrated the technical feasibility of the approach. The first patients were implanted in 2008 and in 2011 we received the CE-mark for removal of refractory ascites due to liver cirrhosis following completion of the PIONEER clinical study. The alfapump® was commercially launched at the EASL meeting in 2012 and in the same year the CE-mark was received for removal of malignant ascites.
Since then we have continued to invest in the clinical, technical and commercial development of the alfapump®. This includes the completion of the MOSAIC IDE feasibility study in North America in patients with liver recurrent and refractory ascites and the publication of the results of the European randomised controlled trial and the initial results of the Post-Marketing Surveillance Registry in patients with liver refractory ascites.
In 2017, we established DSR, a new therapy under development for the treatment of volume overload in heart failure, in collaboration with Dr. Jeffrey Testani, Associate Professor at Yale University. Pre-clinical proof of concept results were presented at EuroPCR 2018 and HFSA 2018.
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.